Medically reviewed by Danielle Weiss, MD Key Takeaways Taking rapid-acting insulin is the fastest way to lower high blood ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

In a March 16 press release, the French drugmaker, which currently has its U.S. headquarters in Bridgewater, said the changes are slated to go into effect Jan. 1, 2024. Along with cutting down the ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

Diabetes mellitus is a problem more and more people suffer from nowadays. There are two main types of diabetes – type 1 (when people’s bodies cannot produce enough insulin on their own) and type 2 ...

March 16 (UPI) --A third drug company is cutting the price of insulin to $35, following competitors Eli Lilly and Novo Nordisk in heeding pressure from the Biden administration. Sanofi's Lantus ...

Sanofi announced it would slash the price of its insulin Thursday evening, joining Novo Nordisk and Eli Lilly in capping costs of the drug used by patients with diabetes. As part of its revised ...

Feb. 27 -- THURSDAY, Feb. 26 (HealthDay News) -- Sanofi-Aventis's Apidra (insulin glulisine) Solostar injection pen has been approved to treat diabetes, the company said Thursday in a news release.